TriSalus Life Sciences (TLSI) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on TriSalus Life Sciences (TLSI) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.19 of bullish evidence against -0.22 bearish.

TriSalus Life Sciences last closed at $4.38, +1.39% on the session.

Against the IVW growth benchmark the position is +0.47% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

4 graded predictions for TLSI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks TriSalus Life Sciences in the 98th percentile on return on equity, where 100 is best.

TriSalus Life Sciences is classified under Health Care / Biotechnology, with a market capitalisation of $266.00M.

StockMap tracks TriSalus Life Sciences as the 207th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite TriSalus Life Sciences ranks 176th of 344 in the group, against a group median of -0.21.